SEC Filing Summary

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, Inc., reported the sale of 7,002 shares of common stock on May 19, 2026. The shares were sold at a weighted average price of $9.0078, with a price range between $8.7421 and $9.0104. This sale was conducted under the company's "sell-to-cover" policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The sales were automatic and not at Mr. Horan's discretion. Following this transaction, Mr. Horan owns 293,450 shares of common stock.